FinancialSports Medicine

The Global Bone Void Fillers Market size is expected to reach $6.1 billion by 2030, rising at a market growth of 7.9% CAGR during the forecast period

The main factor contributing to the rise of bone fracture, particularly in children, is a particular sport’s year-round participation. Bone fracture is expected to acquire more than 53% share of the market by 2030.

New York, July 31, 2023 (GLOBE NEWSWIRE) — announces the release of the report “Global Bone Void Fillers Market Size, Share & Industry Trends Analysis Report By Type, By Form, By Application, By End User, By Regional Outlook and Forecast, 2023 – 2030” –

About 30 million children and teenagers in the United States take part in organized sports of some kind, and each year, these athletes suffer more than 3.5 million injuries that limit their ability to play for a period of time. Sports-related injuries account for nearly one-third of all injuries sustained by children. Sprains and strains are the most typical types of injuries. Undoubtedly, some sports are riskier than others. For instance, it is logical to anticipate that contact sports like football will cause more injuries than noncontact activities like swimming.

Sports-related injuries affect more than 775,000 kids aged 14 and under, who receive annual treatment in hospital emergency rooms. Sports-related injuries are therefore growing more frequent, especially in young people, which is expected to increase demand for bone void fillers. Some of the factors impacting the market are growing attention toward launching antibiotic eluting bone void fillers, rising acceptance of synthetic BVF, and lesser availability and clinical barriers.

Clinical restrictions, like bone infection after surgery, have heightened interest in using antibiotic-eluting void fillers. The market participants are focusing on accelerating R&D efforts and offering antibiotic-eluting void fillers that have also decreased bone infection while undergoing therapy. The introduction of antibiotic-eluting bone void fillers reflects the expanding demand for better infection control methods in orthopedic procedures. The launch of such cutting-edge products is projected to drive the market’s expansion over the forecast period. Because they provide several advantages over conventional bone graft materials, synthetic bone void fillers (BVF) have increased usage in recent years. In place of autografts or allografts—which are taken from the patient’s own body—synthetic BVFs are made-from-scratch materials. The market is predicted to develop due to the rising use of artificial bone void fillers such as calcium sulfate and tricalcium phosphate. The revenue generated was significantly lower in 2020 than it was in 2019. However, in 2021, elective procedures—including orthopedic & trauma surgery—began to resume as the government-imposed restrictions in various countries were removed. Due to several circumstances, including stringent requirements, implementing COVID-19 norms in public settings, and lifting travel restrictions, the number of patients and surgeries recovered. As a result, there was more demand for these products in 2021. Market growth prospects are anticipated to be consistent.

However, demand is declining due to various clinical limitations and inadequate bone void filling substance penetration. The major dangers and hazards associated with its usage, such as infection of soft tissue & bone, insufficient or non-existent bone growth, filler rupture, etc., cause this declining acceptance. Clinicians may be unsure of the best way to utilize and how these fillers will perform due to a lack of high-quality trials or a lack of long-term data. Therefore, these limitations are limiting the market’s ability to grow.

Type Outlook

Based on type, the market is segmented into demineralized bone matrix, calcium phosphate bone graft substitute, collagen matrix, and others. The calcium phosphate bone graft substitute segment acquired a substantial revenue share in the market in 2022. Bone void fillers frequently use calcium phosphate as a replacement for bone grafts. Using a bone void filler can fill in any gaps or defects in a bone, including those caused by bone cysts, fractures, or disease- or trauma-induced bone loss. Because of their biocompatibility and osteoconductive qualities, replacements made of calcium phosphate are frequently used for this purpose.

Form Outlook

On the basis of form, the market is segmented into gel & putty, granules, and others. In 2022, the gel & putty segment witnessed the largest revenue share in the market. The segment’s significant growth can be the result of the more non-invasive and minimally invasive operations being performed these days. Calcium phosphate-based substances, like hydroxyapatite (HA) or tricalcium phosphate (TCP) that enhance osteoconductivity and assist bone regeneration can be present in both gel & putty-based bone void fillers.

Application Outlook

On the basis of application, the market is bifurcated into spine fusion, bone fracture and others. In 2022, the spine fusion covered a considerable segment revenue share in the market. To encourage the fusing of the spinal bones (vertebrae) and produce a solid and stable spinal column, bone void fillers are an essential component of spinal fusion surgeries. In a spine fusion, the choice of bone void fillers is influenced by several variables, including the specific surgical approach, the location & size of the bone void, the patient’s health, and the surgeon’s personal preferences. Based on the treatment’s particular needs and the filler material’s desired qualities, other types of bone graft substitutes, such as granules, putty, or gel-based fillers, may be employed.

End User Outlook

By end user, the market is fragmented into hospital, specialty clinics, and others. In 2022, the hospital segment dominated the market with the maximum revenue share. The expansion of hospitals in both developed and developing nations is blamed for the growth. In addition, it is anticipated that during the anticipated timeframe, a sizable patient pool consulting hospitals to receive treatment and an increase in the number of orthopedic treatments performed in hospital facilities will support segmental expansion.

Regional Outlook

Region wise, the market is analysed across North America, Europe, Asia Pacific, and LAMEA. In 2022, the North America region led the market by generating the highest revenue share. This is attributable to the increased use of artificial bone void fillers, a sizable bone void filler business, the presence of a sophisticated healthcare system, and the widespread availability of bone void fillers.

The market research report covers the analysis of key stake holders of the market. Key companies profiled in the report include Medtronic PLC, DePuy Synthes (Johnson & Johnson), Orthofix Medical, Inc., Stryker Corporation, Zimmer Biomet Holdings, Inc., Smith & Nephew PLC, NuVasive, Inc., Baxter International, Inc., Biocomposites Ltd., and Arthrex, Inc.

Strategies Deployed in Bone Void Fillers Market

Feb-2023: NuVasive got an FDA 510(k) approval Modulus Cervical interbody implant to be used with a bone void filler. The approval shows a notable milestone towards the aim to broaden companies advanced materials integration of Modulus and Attrax Putty to its cervical interbody into the C360 offerings.

Mar-2022: Orthofix came into partnership with MTF Biologics, a global nonprofit organization. Following this partnership, MTF Biologics would be the sole provider of the MTF allograft portfolio. The addition of the Legacy demineralized bone line would broaden its biologic suite, enhancing the options available and providing a valuable solution for its customers and patients.

Feb-2022: Orthofix Medical announced the launch of The Opus BA solution, a bioactive bone graft for spine procedures. The product would be utilized to fill bone voids or gaps in the skeletal system for lumbar and cervical spine fusion procedures.

Feb-2022: Johnson & Johnson’s DePuy Synthes acquired CrossRoads Extremity Systems, a provider of foot and ankle implant systems. Through this acquisition, DePuy Synthes aims to propel its podiatric, orthopaedic, and MedTech advancements from both external and internal innovation.

Jan-2022: NuVasive, Inc. received FDA approval for expanded indications of usage for Attrax Putty with its complete thoracolumbar interbody offerings for spine surgery. The Attrax Putty is a synthetic, osteoconductive, and bioactive bone void filler developed to lead bone fusion. The approval would advance the standard of spine care – while offering better economic value to NuVasive’s customers.

Sep-2021: Orthofix Medical Inc. introduced the Opus Mg Set osteoconductive scaffold, a synthetic magnesium-based bone void filler for orthopaedic procedures. The launched product offers a procedure-specific solution for orthopaedic fracture care and trauma applications by filling non-structural bony voids or gaps at the time of surgery.

Jul-2021: Arthrex partnered with Celularity Inc., a clinical-stage biotechnology company engaged in the development of biomaterial and cell therapies products. Under this partnership, both companies would aim to distribute and market Cellularity’s biomaterial products for sports medicine and orthopaedic surgery.

Mar-2020: Biocomposites launched STIMULAN® Rapid Cure 3cc, an addition to the company’s US product suite targeting smaller voids in the foot and ankle, orthopaedic reconstruction, and trauma. The launch would be developed particularly for smaller voids in the foot and ankle, orthopaedic reconstruction, and trauma procedures.

Jun-2019: Medtronic acquired Titan Spine, a titanium spine interbody implant and surface technology company. This acquisition strengthens Medtronic’s position as a leading company in procedural solutions for spine surgery.

Apr-2019: Smith & Nephew plc took over Osiris Therapeutics, Inc., a stem cell company engaged in developing and commercializing regenerative medicine products consisting of skin, bone graft, and articular cartilage substitutes. This acquisition would boost the growth of Smith & Nephew’s Advanced Wound Management franchise.

Apr-2019: Stryker Corporation completed the acquisition of Wright Medical, a global device company that specializes in extremities. Under this acquisition, Stryker would combine the complementary strengths and collective resources and advance its wide platform of extremities and biologics technologies.

Feb-2019: Medtronic plc introduced Grafton Demineralized Bone Matrix (DBM) bone grafting product for spine and orthopaedic procedures, across Japan. The Grafton DBM is a bone graft substitute, bone void filler, and bone graft extender in bony voids or gaps of the skeletal system.

Scope of the Study

Market Segments covered in the Report:

By Type

• Demineralized Bone Matrix

• Calcium phosphate Bone Graft Substitute

• Collagen Matrix

• Others

By Form

• Gel & Putty

• Granules

• Others

By Application

• Bone Fracture

• Spine Fusion

• Others

By End User

• Hospital

• Specialty Clinics

• Others

By Geography

• North America

o US

o Canada

o Mexico

o Rest of North America

• Europe

o Germany

o UK

o France

o Russia

o Spain

o Italy

o Rest of Europe

• Asia Pacific

o China

o Japan

o India

o South Korea

o Singapore

o Malaysia

o Rest of Asia Pacific


o Brazil

o Argentina


o Saudi Arabia

o South Africa

o Nigeria

o Rest of LAMEA

Companies Profiled

• Medtronic PLC

• DePuy Synthes (Johnson & Johnson)

• Orthofix Medical, Inc.

• Stryker Corporation

• Zimmer Biomet Holdings, Inc.

• Smith & Nephew PLC

• NuVasive, Inc.

• Baxter International, Inc.

• Biocomposites Ltd.

• Arthrex, Inc.

Unique Offerings

• Exhaustive coverage

• Highest number of market tables and figures

• Subscription based model available

• Guaranteed best price

• Assured post sales research support with 10% customization free
Read the full report:

About Reportlinker
ReportLinker is an award-winning market research solution. Reportlinker finds and organizes the latest industry data so you get all the market research you need – instantly, in one place.

Contact Data

US: (339)-368-6001
Intl: +1 339-368-6001

Josh Sandberg

Josh Sandberg is the President and CEO of Ortho Spine Partners and sits on several company and industry related Boards. He also is the Creator and Editor of OrthoSpineNews.

Related Articles

Back to top button